MA40624A - Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant - Google Patents

Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant

Info

Publication number
MA40624A
MA40624A MA040624A MA40624A MA40624A MA 40624 A MA40624 A MA 40624A MA 040624 A MA040624 A MA 040624A MA 40624 A MA40624 A MA 40624A MA 40624 A MA40624 A MA 40624A
Authority
MA
Morocco
Prior art keywords
superior
papilloma virus
human papilloma
vaccine containing
virus antigens
Prior art date
Application number
MA040624A
Other languages
English (en)
French (fr)
Inventor
Viviana Giannino
Reinhard Glueck
Gaurav Gupta
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of MA40624A publication Critical patent/MA40624A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MA040624A 2014-09-11 2015-09-11 Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant MA40624A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2905MU2014 2014-09-11

Publications (1)

Publication Number Publication Date
MA40624A true MA40624A (fr) 2016-03-17

Family

ID=54843870

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040624A MA40624A (fr) 2014-09-11 2015-09-11 Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant

Country Status (10)

Country Link
EP (1) EP3191505A2 (ja)
JP (1) JP2017528137A (ja)
CN (1) CN107002085A (ja)
AR (1) AR101840A1 (ja)
AU (1) AU2015313756A1 (ja)
BR (1) BR112017004181A2 (ja)
CA (1) CA2958222A1 (ja)
EA (1) EA201790365A1 (ja)
MA (1) MA40624A (ja)
WO (1) WO2016038625A2 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117187262A (zh) * 2014-02-18 2023-12-08 上海泽润生物科技有限公司 重组人乳头瘤病毒蛋白表达
CA3002323A1 (en) 2015-10-19 2017-04-27 Cadila Healthcare Limited New adjuvant and vaccine composition containing the same
CN109750049B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒52亚型蛋白表达
US11946048B2 (en) 2017-11-14 2024-04-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Non-human papillomaviruses for gene delivery in vitro and in vivo
US11389519B2 (en) * 2018-06-11 2022-07-19 Inventprise, Llc Virus-like particle conjugates
BR102020006846A2 (pt) * 2020-04-03 2021-12-07 Imunoscan Engenharia Molecular Ltda Peptídeos sintéticos miméticos a proteína l1 do hpv, método de diagnóstico de hpv, sistema de diagnóstico de hpv, composição farmacêutica e uso dos mesmos no tratamento ou profilaxia do hpv

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213185T3 (es) * 1995-11-15 2004-08-16 MERCK & CO., INC. Particulas de tipo virus hpv11 sinteticas.
JP4598201B2 (ja) * 1997-04-08 2010-12-15 メルク・シャープ・エンド・ドーム・コーポレイション 安定化ヒトパピローマウイルス製剤
DK1015561T3 (da) * 1997-09-05 2006-11-13 Medimmune Inc In vitro-fremgangsmåde til adskillelse/gensamling af papillomavirus-lignende partikler (VLP'er)
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
CN101115766B (zh) * 2004-06-18 2013-05-08 印度免疫有限公司 用于抗人乳头瘤病毒型16的salmonella疫苗菌株的密码子经优化的hpv16l1
CN101487009B (zh) * 2008-01-15 2012-11-21 上海泽润生物科技有限公司 用毕赤酵母表达系统制备抗人乳头瘤病毒16型感染的疫苗的方法
EP2223933B1 (en) * 2007-11-23 2016-01-27 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein l1 of human papilloma viruses
AU2009275909A1 (en) * 2008-07-31 2010-02-04 Glaxosmithkline Biologicals S.A. Vaccine against HPV
US9566323B2 (en) * 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
CN102154325B (zh) * 2011-01-01 2013-08-21 上海生物制品研究所有限责任公司 针对人乳头瘤状病毒的疫苗及其制法和用途
CA2835972A1 (en) * 2011-05-13 2012-11-22 Folia Biotech Inc. Virus-like particles and process for preparing same
EP2723371B1 (en) * 2011-06-24 2019-10-23 Merck Sharp & Dohme Corp. Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
KR101559622B1 (ko) * 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
CN103667319B (zh) * 2012-09-10 2017-09-26 同济大学 抗人乳头瘤病毒的三价疫苗及其制法和用途

Also Published As

Publication number Publication date
CN107002085A (zh) 2017-08-01
EP3191505A2 (en) 2017-07-19
BR112017004181A2 (pt) 2017-12-05
EA201790365A1 (ru) 2017-07-31
WO2016038625A3 (en) 2016-04-28
AU2015313756A1 (en) 2017-03-09
CA2958222A1 (en) 2016-03-17
WO2016038625A2 (en) 2016-03-17
AR101840A1 (es) 2017-01-18
JP2017528137A (ja) 2017-09-28

Similar Documents

Publication Publication Date Title
MA40624A (fr) Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2018002106A (es) Vacunas terapeuticas contra el hpv18.
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12017500727A1 (en) Modified virus-like particles of cmv
WO2016090327A3 (en) Antibodies targeting b-cell maturation antigen and methods of use
MY181175A (en) Therapeutic hpv16 vaccines
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
TW201613963A (en) Anti-JAGGED1 antibodies and methods of use
MX2019004690A (es) Constructos de anticuerpos.
EP3200831A4 (en) Vaccines having an antigen and interleukin-21 as an adjuvant
EP3515482A4 (en) COMBINATION OF NEW VACCINE AGAINST ZIKA VIRUS AND DNA ANTIBODY CONSTRUCTS FOR USE AGAINST ZIKA VIRUS
PL3355915T3 (pl) Szczepionki zawierające cząstki wirusopodobne (VLP) parwowirusa psów (CPV) i ich zastosowania
TN2014000518A1 (en) Reassortant btv and ahsv vaccines
MX2017008286A (es) Nuevos metodos para el despliegue de peptidos ciclicos en particulas de bacteriofagos.
MX2017016896A (es) Vacunas inactivadas contra la influenza canina, metodos para elaborarlas y sus usos.
MX356325B (es) Composicion para cuidado personal.
SG11201912454SA (en) Virus-like particles comprising zika antigen
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
EP3403671C0 (en) VACCINE WITH IMMOBILIZED VIRUS PARTICLES
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
EP3170509A4 (en) Vaccine containing virus-like particles
WO2015196180A3 (en) Influenza vaccines and methods of use thereof
MX2024007379A (es) Vacunas para el virus del papiloma humano y metodos para su uso.